Clinical Trial: GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891364) titled 'GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease' on Oct. 07.

Brief Summary: This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GBP-213 in patients with autosomal dominant polycystic kidney disease (ADPKD).

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Autosomal Dominant Polycystic Kidney

Intervention: DRUG: GBP-213

Subcutaneous injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: RenJi Hospital

Disclaimer: Curated by HT Syndication....